Suzhou Haowei Medical Technology Co., Ltd specializes in the technological innovation of "Drug-Device Combined Product" technique, aiming to help TACE treatment fulfil clinical unmet needs through contin- uous research and development and innovation. A series of innovative products such as drug-eluting microspheres, resorbable microspheres, radioactive microspheres, balloon occluded microcatheters and steerable microcatheters developed by the company have gradually entered the stage of commercial- ization.
UNIFORM PARTICLE SIZE

1- Precise drug delivery and vascular embolization for different clinical scenarios, such as emboli- zation of hypervascularized tumors including hepatoma, and peripheral arteriovenous malfor- mations.

2- Precise calibrated microspheres (CV controlled within 5%-10%) as small as 70µm show greater distal penetration and more effective embolization than larger microspheres without influencing patient safety [1, 2].

3- Study demonstrated that smaller size beads doxorubicin DEBs are superior to larger ones in terms of achieving a tumor response and have shown their therapeutic efficacy as a bridge to liver transplantation [3, 4].

4- The use of smaller bead sizes may result in improved tumor penetration resulting in more dura- ble treatment response [5] have further shown the use of 40 µm beads to be safe [6], even with concurrent systemic chemotherapy.
 
1- Ready-for-use, no need to reconstitution.

2- Excellent effect of embolization.

3- DEB-TACE is effective and safe for the treatment of HCC, and interventions with small-caliber DEBs (< 100 µm) is recommended. TACE treatment with small-caliber DEBs (< 100 µm) is indicated for super-selective embolization of feeding arteries in order to prevent major complications [7].

4- DEB-TACE is associated with a better objective response, disease control, and lower all-cause mortality with severe complications compared to C-TACE treatment [8].

5- Small particle DEBIRI using 40 and 75 µm drug-eluting beads is safe and provides survival benefits com- parable to larger bead sizes [9].

6- This recent meta-analysis shows that DEB-TACE provides significantly better tumor response compared with conventional TACE. One-year and 2-year survival are better with DEB-TACE. In addition, DEB-TACE is as safe as conventional TACE [10].

7- The meta-analysis using a fixed-effects model showed significantly better objective tumor response rate for DEB-TACE compared with conventional TACE (OR = 1.92, 95% CI [1.34, 2.77]; P = 0.0004), with a relative risk difference of 0.15 [0.07, 0.24] (P = 0.0003) [10].


[allow_numbers]